Informations générales (source: ClinicalTrials.gov)
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Interventional
Phase 1
BeOne Medicines (Voir sur ClinicalTrials)
juillet 2024
mai 2028
04 juin 2026
This is a first-in-human (FIH) clinical study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of
BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or
without bevacizumab. The study will enroll participants with locally advanced or
metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric
cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3
(GPC3)-positive squamous non-small cell lung cancer (NSCLC).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Christophe MASSARD | 03/06/2026 07:55:05 | Contacter | ||
Critères
Tous
1. Participants must have one of the following unresectable, locally advanced, or
metastatic tumor types:
1. Hepatocellular carcinoma (HCC): Histologically or cytologically confirmed HCC
that is either Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC Stage B
that is not amenable to, or has progressed after, loco-regional therapy and is
not eligible for a curative treatment approach.
2. Alpha-fetoprotein (AFP)-producing gastric cancer (GC): Histologically confirmed
GC with AFP > 20 ng/mL in blood or tumor tissue positive for AFP by a validated
immunohistochemistry (IHC) assay based on local or central testing.
3. Germ cell tumors: Histologically confirmed germ cell tumors including
extragonadal yolk sac tumors (e.g., located in the mediastinum, vagina, brain,
retroperitoneum), and non-dysgerminomas for which no further curative systemic
treatment options exist.
4. Glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC):
Histologically confirmed GPC3-positive squamous NSCLC with prior exposure to a
checkpoint inhibitor (CPI).
2. At least one evaluable lesion for dose escalation, and
3. At least one measurable lesion for safety expansion, as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
5. Adequate organ function as defined in the protocol.
6. Provision of tumor tissue samples is required for specified parts of the study.
Key Exclusion Criteria:
1. Prior therapy directed against glypican-3 (GPC3) or the T-cell costimulatory
receptor 4-1BB (CD137).
2. Active leptomeningeal disease or uncontrolled/untreated brain metastases.
3. Active autoimmune disease or a history of autoimmune disease with potential for
relapse.
4. Any malignancy diagnosed ≤ 2 years before the first dose of study drug(s), except:
The cancer type under investigation in this study, or Locally recurring malignancies
previously treated with curative intent.
5. Requirement for systemic corticosteroids (> 10 mg/day prednisone or equivalent) or
other immunosuppressive therapy within 14 days prior to the first dose of study
drug(s).
6. Certain comorbidities involving the lungs, heart, bleeding conditions, or active
infections, as defined in the protocol.
Note: Additional protocol-defined inclusion and exclusion criteria may apply.